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Background: We tested the hypothesis that the course and outcome of juvenile dermatomyositis (JDM) in children
seen at one center with the JDM disease onset at or below three years of age is different from that in the children
with disease onset at greater than three years of age.
Methods: Institutional Review Board approval was obtained to retrospectively review the charts of 78 patients from
age 0–18 years with JDM seen in the pediatric rheumatology clinic at Nationwide Children’s Hospital in Columbus,
Ohio over the past 23 years from January 1988. The diagnosis was made by the treating pediatric rheumatologist.
Not all the patients met the Bohan and Peter criteria, as muscle biopsy and EMG were not always performed and
we utilized a modified JDM criteria. The data regarding disease course and outcome were collected as of the last
clinic follow-up or to July 1, 2010. We used the Wilcoxon Two-Sample test to compare numerical variables between
two age groups, and used logistic regression to compare categorical variables between two age groups in SAS
9.1.3. Minitab-16 was used to calculate various mean, median, modes, standard deviations and range. For survival
analysis, we used Kaplan-Meier method with log-rank test.
Results: The mean age of onset in the two groups at Nationwide Children’s Hospital was 27 months and
91 months. The mean times between onset of symptoms to diagnosis in the younger and older age groups was
5.6 months and 4.5 months, respectively, not a statistically significant difference. The younger onset group had
more females (p=0.05) and their disease onset occurred less frequently during the typical winter-spring seasons
(p=0.031). The younger onset group was more likely to have a preceding fever (p=0.029) and family history of
autoimmune diseases (p=0.012). The younger onset group was less likely to have heliotrope rash (p=0.04), Gottron’s
sign (p=0.049), capillary loop abnormalities (p=0.010), or elevations in creatine kinase (CK, p=0.022), aspartate
aminotransferase (AST, p=0.021) or aldolase (p=0.035). The younger onset group was treated less often with pulse
methylprednisolone at diagnosis (p=0.043) and less often with hydroxychloroquine (p=0.035). There were no
differences between the two groups regarding initial oral steroid dose (p=0.8017), number of patients who received
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methotrexate at diagnosis (p=0.709), and the number who ever received other immunosuppressants (p=0.323). The
mean and maximum duration (mean duration 24.3 months vs. 35.2 months, maximum duration 51 vs. 124 months
in younger and older onset group respectively) of methotrexate therapy, and the mean and maximum duration of
oral steroid therapy (Mean duration 16.8 months vs. 33.3 months, maximum duration 50 vs. 151 months in younger
and older onset group respectively), was shorter in the younger group. The younger onset patients were less likely
to have active disease at 5 years (9% vs. 35.7%, p=0.015) and 10 years post-diagnosis (9% vs. 45.1%, p=0.011, Table
7). The younger patients were less likely to have osteonecrosis (p=0.023). Two disease-related deaths occurred in
the younger group, none in the older group. The results of the survival analysis showed that the difference
between the age groups was statistically significant (p < 0.012). The sex and race were not significant (p> 0.26 and
p>0.95, respectively).
Conclusions: There were significant differences between JDM patients with disease onset at or below age three
years at our center, compared to their older counterparts. Younger patients in our cohort had fewer typical findings
at diagnosis and a milder disease course without needing as long a duration of corticosteroids and
immunosuppression. Patients with a younger onset had a higher mortality rate but mortalities were unusual and
numbers small. The younger group had a similar complication rate compared to the older onset patients, except
for osteonecrosis which was higher in the older onset group. These findings differ from the previous reports that a
younger age of onset in JDM is often associated with a more severe disease, as results at our center suggest that
children with younger onset JDM appear to be atypical but may do well compared to the older JDM patients.
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Juvenile dermatomyositis (JDM) is an autoimmune disease
of blood vessels in children and adolescents that primarily
affects muscles and skin. The mean age of onset is 7 years
of age and girls have a slight predominance [1]. The pre-
senting features may include a disease pattern of an erythe-
matosus rash on the cheeks, a red to violacious rash on the
eyelids with edema, raised red papules on the extensor sur-
faces of finger joints, abnormal nailbed capillaries, and a
red rash on the elbows, knees, and ankles. The hallmark
feature is proximal muscle weakness that may be severe
and debilitating [1,2].
The course of juvenile dermatomyositis has improved
dramatically over the last 60 years. Prior to the 1950’s
when daily corticosteroids started to be used consistently,
1/3 of JDM children recovered, 1/3 of JDM children were
disabled, and 1/3 died [3]. Now after earlier diagnosis and
aggressive treatment with corticosteroids and immuno-
suppressive drugs, JDM patients do much better with
much less morbidity and mortality (<1% mortality) [4-12].
Prognostic factors are still lacking that might direct pe-
diatric rheumatologists to the best treatment approach for
each child as the experiences vary with different patient
populations and research centers [9-12].
At Nationwide Children’s Hospital, the rheumatology
service has often cared for young children with the onset
of JDM at three years or less over the last 25 years. The
disease course of JDM children we have seen varies consi-
derably, making individual prognosis and treatment needs
difficult to predict. There is little published literature com-
paring clinical presentation, disease course, and outcomeof juvenile dermatomyositis in young children versus older
children (e.g. disease onset below and above age 3 years).
It was our hypothesis that this subset of JDM children
may be different than the patients with an older onset of
the disease at our institution in their clinical features,
course, and treatment. In this study we therefore investi-
gated age-specific disease characteristics and differences
that may influence JDM disease course and treatment
options using our cohort of JDM patients with a relatively
large number of younger onset patients.
Methods
Nationwide Childrens Hospital Institutional Review Board
(IRB) approval was obtained for this study. We identified
85 patients with a medical record diagnosis (ICD-9 coding)
of JDM at Nationwide Children’s Hospital from January
1988 to July 2010. After a preliminary review of electronic
medical records and paper charts, 7 patients were excluded
because they developed a rheumatic overlap syndrome or
mixed connective tissue disease. We included 78 patients,
all younger than 18 years of age at onset of disease.
Nineteen were at or below 3 years of age and 59 were
above 3 years of age at onset of symptoms of JDM. These
charts were reviewed retrospectively to collect informa-
tion for a period starting at their date of presentation
to the last clinic follow-up, or to July 1, 2010. As a part
of the rheumatology practice, the standard format of
outpatient assessment clinical charts designed for JDM
were used in clinics. After initial assessment/admission the
patients are seen every 6–12 weeks in most cases depen-
ding on their individual needs. We collected information
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the diagnosis, at 6 months post diagnosis, 1 year, 3 years,
5 years and then 10 years post-diagnosis. Demographic
data was collected from medical record of all the JDM
patients. Only 23 patients had race/ethnicity information
in medical records; thus information on this variable, al-
though important, could not be included. We examined
the raw data from our retrospective chart review and
found significant differences in the several disease aspects
such as demographic and outcome parameters between
those who had onset at three years or below compared to
those above three years of age.
We used a modification of the diagnostic criteria pro-
posed by Bohan and Peter [3]. The original criteria
permit a definite diagnosis of dermatomyositis if there
are characteristic cutaneous changes, and 3 of 4 other
manifestations: symmetric proximal muscle weakness,
elevated muscle enzymes (CK, AST, LDH, or aldolase),
electromyographic evidence of myopathy and denerv-
ation, and characteristic muscle histopathology. Probable
JDM is defined by the Bohan and Peter criteria as the
presence of characteristic cutaneous changes and two of
the four other manifestations.
In our modification of the Bohan and Peter criteria, we
included typical abnormalities on muscle magnetic reso-
nance imaging (MRI) as a 5th manifestation. When per-
forming MRI on JDM patients at Nationwide Children’sFigure 1 Survival analysis: Kaplan-Meier method with log-rank test fo
show, the difference the age group was statistically significant (p < 0.012).
respectively). Censored = some of the subjects had not experienced the ou
because they had dropped out, i.e., discharged, lost to followup or died beHospital in recent years, a standardized MRI protocol se-
quence was used. MRI is considered a highly sensitive tool
for the diagnosis of muscle inflammation. Although it has
low specificity; it provides information on muscle inflam-
mation with almost same specificity as an EMG would. In
a typical JDM MRI, we look for documented extent and
intensity of the muscle abnormalities. The inflammation is
usually symmetric and classically involves the proximal
muscle groups in dermatomyositis. We look for high sig-
nal intensity in the active phase on STIR and fat-saturated
gadolinium-enhanced T1-weighted images as a part of
JDM protocol for MRI. In the chronic phase, we consider
fatty atrophy of the musculature that is seen on T1-
weighted images as suggestive of IIMD/JDM [13-15].
For our study purposes, definite JDM was defined
as characteristic cutaneous changes plus 3 of 5 other
manifestations, and probable JDM as characteristic cuta-
neous changes plus 2 of 5 other manifestations. Of our 78
patients, 14 from the younger onset group and 56 from
the older onset group had definite dermatomyositis
according to these modified criteria. Six patients (4 from
the younger onset group and 2 from the older onset
group) never developed significant rash before treatment,
but were included in the study due to the muscle biopsy
results very typical for JDM (Figure 1). Two patients
included in this study were classified as probable JDM
(one each from the younger and older onset groups).r comparison of survival curves. The results of the survival analysis
The Sex and race were not significant (p > 0.26 and p > 0.95,
tcome of interest by the end of the follow-up period of ten years
fore reaching the outcome of interest.
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ical muscle weakness, active skin rash, abnormal muscle
enzymes, neopterin concentrations, von Willebrand anti-
gen level, and histological evidence with or without
elevated inflammatory markers. No single physical exam
muscle strength tool, such as the CMAS [16], was used in
all cases in this study, due in part to the difficulty of accur-
ately assessing strength in very young children and the
lack of validity of these tools at that young age. For this
reason, CMAS results are not reported in this study for
patients seen after the CMAS was developed. The muscle
strength testing in younger children had to rely more on
observation of gross motor functioning than classic
muscle testing or the CMAS, but the testing by these
three experienced pediatric rheumatologists was felt to be
accurate and reliable.
The following information was collected from both
groups: Demographic details, season at onset, clinical
presentation, lab results, disease course, treatments used,
response to treatment, initial and final heights, complica-
tions, and outcome at 1, 5, and 10 years post-diagnosis.
We recorded the time required to achieve the first remis-
sion and also time required to reach normal muscle
strength for the first time after disease onset. We also
compared the time between the onset of symptoms and
diagnosis, patterns of remissions and relapses, and the
effect of disease on growth of these patients.
As JDM frequently goes into remission within 2–3 years
of treatment initiation [3,4,13,14], three years may be
considered as one disease cycle. Different researchers have
defined disease course differently [1]. For the purposes of
this study, the course of the disease was classified as
follows;
Monocyclic course
The diseases course with a single episode of the disease
with only one remission and no relapses.
Polycyclic
More than one remission and relapse in the diseases
course of any duration.
Chronic continuous
Continuously active disease course over 4 years without
definite remissions.
Relapse
Recurrence or increase in the clinical, lab or radiologic
parameters of disease activity in a patient in whom such
parameters had either improved or were reduced to re-
flect lower disease activity. Data collected for this was
from physical examination of skin i.e. rash (Gottron’s,
heliotrope/nailfold capillary abnormalities), muscle strengthon clinical examination, MRI (JDM protocol), muscle
enzymes) as applicable.
Remission
Absence of clinical and lab/imaging parameters of dis-
ease activity for 6 months or more without any treat-
ment. The data collected for this parameter was the
same as for the relapse.
In the standardized charts for JDM patients, the
patients were assessed for complications at the time of
diagnosis and thereafter during each clinic visit. Three
patients in this study, which included one from older
age group and two from younger age group, had an ul-
cerative course of disease. Both the patients from younger
age group died due to their disease (see Appendix A & B
for the details).
Statistics
We use Wilcoxon Two-Sample test to compare nume-
rical variables between two age groups, and use logistic
regression to compare categorical variables between two
age groups in SAS 9.1.3. Minitab-16 was used to calcu-
late various mean, median, modes, standard deviations
and range. For survival analysis, we used Kaplan-Meier
method with log-rank test.
Results
The mean age of onset in the two groups of JDM patients
seen at Nationwide Children’s Hospital was 27 months
and 91 months. The mean intervals between onset of
symptoms to diagnosis in younger and older age groups
were 5.6 months and 4.5 months respectively. The diffe-
rence was not statistically significant. The younger onset
group had more females than males (p=0.05) and their
disease onset occurred less frequently during the most
common JDM onset peak of the late winter-spring months
(January to May, p = 0.031) [15-17] (Table 1).
The younger onset group was more likely to have a
preceding fever (p=0.029) and family history of auto-
immune diseases (p=0.012). Patients in the younger onset
group less often had heliotrope rash (p=0.04), Gottron’s
sign (p=0.049), or nailfold capillary loop abnormalities
(p=0.010), or any JDM rash at all (p=0.049) (Table 2).
They also had a lower frequency of muscle enzyme ele-
vation such as creatine kinase (CK, p=0.032), aspartate
aminotransferase (AST, p=0.021), aldolase (p=0.035), and
lactate dehydrogenase (LDH, p=.042) (Table 3), than the
patients in the older age group.
The younger onset group was treated less often with
pulse methylprednisolone (p=0.043) and hydroxychloro-
quine (p=0.035). These younger children were less likely
to be admitted to the hospital (p=0.043) at the time of
diagnosis. There were no differences between the two
groups in the initial oral steroid dose in mg/kg/day
Table 1 Differences in demographics and seasonal variations




of age at onset
n = 59
Total patients p-value
Average age of onset in months 27 90 78
Females: Males 16/3 (5.3:1) 35/24 (1.4:1) 78
Onset Late Winter – Early Spring (January-May) 11 (57%) 46 (78%) 78 0.031
Onset Summer (June-September) 5 (26%) 6 (10%) 78 0.042
Onset Autumn (October-December) 3 (15%) 7 (12%) 78 0.657
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portion of patients who received methotrexate at diagnosis
(p=0.70), and the proportion of patients of each group
who ever received other immunosuppressive medications
during their disease course (p=0.32) (Tables 4 and 5). No
differences in the frequency of initial use of steroids and
use of methotrexate at diagnosis were found between the
two age groups. The mean and maximum duration of
methotrexate therapy (mean duration 24.3 months vs.
35.2 months, maximum duration 51 vs. 124 months in
younger and older onset group respectively), and the mean
and maximum duration of oral steroid therapy (mean dur-
ation 16.8 months vs. 33.3 months, maximum duration 50
vs. 151 months in the younger and older onset group
respectively), was shorter in the younger group.
Examination of the disease outcome at 1 year, 5 years,
and 10 years revealed differences between the two onset
groups of JDM patients (Table 6). Consistent with their
onset characteristics, at one year post-diagnosis, younger
onset patients were significantly less likely to have ele-
vated muscle enzymes than older onset patients (0% vs.
15%, p=0.018). There was also a trend for a lower persist-
ence of muscle weakness (26% vs. 37%, p=0.461) andTable 2 JDM features at diagnosis
Disease features 3 years of age and
below at onset
n = 19
Preceding fever 14 (73%)
Other systemic symptoms* 5 (26%)
No heliotrope Rash 7 (36%)
No Gottron’s papules 9 (47%)
No rash at all 4 (21%)
No Capillary Loop abnormality 12 (63%)
Swallowing difficulties 3 (15%)
Raynaud’s phenomenon 1 (5%)
Family history of Autoimmune disorders 15 (80%)
* Recurrent troublesome abdominal pain, bloody diarrhea, shortness of breath, tach
system symptoms.
{Swallowing difficulties = 3/19 in younger group, 5/59 in older age group.
Shortness of breath/ tachycardia/ syncope = 2/19 in younger group, 10/59 in old
Abdominal pain/bloody diarrhea/nasal regurgitation = 4/19 in younger group, 1
Symptoms involving central nervous system = 1/19 in younger group, 2/59 in ol
Generally patients had more than one type of systemic symptom.}rash (32% vs. 54%, p=0.126) in the younger onset group
compared to the older group, but neither comparison
reached statistical significance. The younger onset patients
were less likely to have active disease at 5 years (9% vs.
35.7%, p=0.015) and 10 years post diagnosis (9% vs. 45.1%,
p=0.011) (Table 7). Younger age group patients were more
likely to experience a monocyclic course (84.9% vs. 33.8%,
p=0.027) and less likely to experience a polycyclic (p=0.019)
or chronic continuous course (p=0.03) (Table 7).
Complications were evaluated, including serious infec-
tions (patients requiring IV antibiotics and/or hospital ad-
mission for treatment of infection), calcinosis, muscle
atrophy, lipodystrophy, osteonecrosis, growth retardation,
and death. The younger patients were less likely to have
osteonecrosis (5% vs. 17%, p=0.023). Though the differ-
ences in most complication rates did not reach statistical
significance, there were trends. The rates of serious infec-
tions (36% vs. 29%), muscle atrophy (21% vs.15%) and lipo-
dystrophy (16% vs.13%) were slightly higher in the younger
onset group of children, but the rate of calcinosis (15% vs.
22%) was slightly lower. The data on weight percentiles
was not analyzed, because the relative effects of disease ac-
tivity and steroid treatment on weight changes could notAbove 3 years
of age at onset
n = 59
Total patients p-value
21 (35%) 78 0.029
14 (23%) 78 0.82
8 (13%) 78 0.04
4 (6.8%) 78 0.049
2 (3%) 78 0.039
5 (8%) 78 0.010
7 (11%) 78 0.66
5 (8.4%) 78 0.048
26 (44%) 78 0.012
ycardia, syncope, swallowing difficulties, nasal regurgitation, central nervous
er age group.
0/59 in older age group.
der age group.
Table 3 Normal muscle enzymes, ESR, WBC and hemoglobin at diagnosis (diagnosis)







Normal AST 14 (73.6%) 23 (38.9%) 78 0.021
Normal Aldolase 14 (73.6%) 20 (33.8%) 78 0.035
Normal LDH 15 (78.90% ) 25 (42.30%) 78 0.042
Normal CK 14 (73.60%) 25 (42.3%) 78 0.032
Elevated ESR 12 (63% ) 26 (44%) 78 0.152
Elevated WBC None (0) 4 (7%) 78 -
Low Hb (<11gm/dl) 9 (47%) 21 (35%) 78 0.361
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the two groups might have been a major confounder.
Three of the patients had an ulcerative JDM course.
The patient from the older group had chronic continu-
ous course while both the patients from younger age
group died due to their disease (see Appendix A & B for
short clinical histories). Time in months from diagnosis
to reaching near normal muscle strength for the first
time was longer in younger onset age group (10.33 vs.
8.29) as compared to older age group but inability to test
muscle strength due to poor cooperation may be a huge
confounder in younger age of onset group.
For survival analysis, we used Kaplan-Meier method
with log-rank test for comparison of survival curves
(Figure 1). The results of the survival analysis show that
the differences between the age groups were statistically
significant (p < 0.012). The sex and race were not signifi-
cant (p > 0.26 and p > 0.95, respectively).
In contrast to their milder overall course, disease-related
deaths were more frequent in the younger onset age group
(2) than in the older onset group (0) (p < 0.02). One of the
2 patients in the younger group who died had severeTable 4 Management at diagnosis
Management at diagnosis
(Within 4 weeks of the diagnosis)
3 Years of age and
below at onset
n = 19
Received admission at diagnosis 6 (31%)
Initial dose of oral prednisone Dose in mg /kg/day
n = 16
Mean = 1.4
St Dev = 0.504
Median = 1.450
Range = 0.75 to 2
Mode = 2
Received pulse steroids at the diagnosis 6 (31%)
Received treatment with methotrexate
at the diagnosis
12 (63%)ulcerative disease involving the skin and intestinal tract
(see Appendix A and B).
One potential bias is the use of immunosuppressive
medications. The immunosuppressive drugs used to treat
JDM have evolved over past 23 years. In our institution,
the immunosuppressives drugs were used over following
approximate time lines: methotrexate by 1980, cyclospo-
rine by 1990, mycophenolate mofetil (MMF) by 2000,
TNF-α inhibitors and B-Cell depletion from 2000. We be-
lieve that this time course of treatment is typical of
pediatric rheumatology centers with access to these drugs
and ability of patients to afford these drugs.
Discussion
The goal of this study was to compare the onset characte-
ristics and course of dermatomyositis in very young chil-
dren (≤3 years old) and in older children. We recognized
that establishing a diagnosis of JDM can be problematic
using the 1975 criteria of Bohan and Peter [3], due to diffi-
culty in assessing muscle strength in younger children,
and a reluctance to perform invasive procedures for diag-




36 (61%) 78 0.043
Dose in mg/kg/day 78 -
n = 54
Mean = 1.423
St Dev = 0.5237
Median = 1.500
Range = 0.27 to 2
Mode = 2
35 (59%) 78 0.043
40 (68%) 78 0.709
Table 5 Treatment received during the course of the disease




of age at onset
n = 59
Total patients p-value
Plaquenil 1 (5%) 17 (29%) 78 0.035
♦ Immunosuppressant 3 (16%) 16 (27%) 78 0.323
IVIG 3 (16%) 17 (29%) 78 0.27
Rituximab 0 (none) 3 (5%) 78 -
• Duration in months of
methotrexate therapy
n=13 n = 48 78 -
Mean = 24.31 Mean = 35.17
St Dev = 15.22 St Dev = 27.20
Median = 23.00 Median = 26.00
Range = 1 to 51 Range = 4 to 124
Mode = 12 Mode = 17, 25
• Duration in months of oral
prednisolone/prednisone therapy
n = 18 n = 55 78 -
Mean = 16.89 Mean = 33.33
St Dev = 13.62 St Dev = 27.62
Median = 19 Median = 23
Range = 1 to 50 Range = 4.5-151
Mode = 19 Mode = 14, 15, 21, 36
♦ Non-methotrexate immunosuppressant: anti-tumor necrosis factor biologics, mycophenolate mofetil, cyclosporine and cyclophosphamide
In the younger group: 12/19 patients were started on MTX at the diagnosis but eventually 13/19 received methotrexate during their disease course. While
in patients with older onset group: 40/59 patients were started on MTX at diagnosis but eventually 48/59 patients received methotrexate during their
disease course.
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many pediatric rheumatologists currently use the MRI,
particularly of the thigh and hip girdle muscles, as a
noninvasive method to identify proximal muscle inflam-
mation. Fat-suppressed T2-weighted sequences or STIR
(short tau inversion recovery) sequences are sensitive for
demonstration of muscle edema, which typically occurs
in a patchy but relatively symmetric distribution in JDM
[13-15]. The addition of typical MRI abnormalities was
ranked highly in a recent consensus conference to developTable 6 Course of JDM at 1 year, 5 year, and 10 years from th







Persistent muscle weakness 5/19 (26%) 22
Persistent rash 6/19 (31%) 32
Elevated muscle enzymes 0/19 (none) 15
5 Years





Active disease 1 (9%) (8/19 patients were
discharged/lost followup)
14
direvised criteria for JDM. Consistent with newer trends in
pediatric rheumatology practice and the likely future in-
clusion of MRI in formal diagnostic criteria for JDM, we
added typical MRI abnormalities to the diagnostic criteria
for this study. The data was collected retrospectively from
the standardized forms/clinical charts designed for JDM
patients and used in rheumatology clinics at Nationwide
Childrens Hospital.
Age characteristics of our JDM population were simi-





/59 (37%) 78 0.4612
/59 (54%) 78 0.1261
/59 (25%) 78 0.018
78
(35.7%) (17/59 patients were
scharged/lost followup)
53 0.015
(45.1%) (28/59 patients were
scharged/lost followup)
42 0.011
Table 7 Disease course response patterns
Disease course Frequency in 3 years of
age and below at onset
n = 19
Frequency in above
3 years of age at onset
n = 59
p-value
Monocyclic Disease 16 (84.2%) 20 (33.8%) 0.027
Polycyclic 1 (5.2%) 21 (35.5%) 0.019
Chronic continuous 2 (10.5%) 18 (30%) 0.03
Time in months from diagnosis
to first remission
n = 13 n = 37 -
Mean = 23.62 Mean = 26.84
St Dev = 13.72 St Dev = 14.91
Median = 21 Median = 24
Range = 6 to 51 Range = 7 to 78
Mode = 6, 19 Mode = 23, 27
Duration in months of disease
follow up
n = 19 n = 59 -
Mean = 78.4 Mean = 95.10
St Dev = 61.0 St Dev = 62.12
Median = 56.0 Median = 81
Range = 6 to 202 Range = 6 to 211
Mode = 36, 85 Mode = 21, 24, 26
Time in months to reach near
normal muscle strength first time
n = 9 n = 41 -
Mean = 10.33 Mean = 8.29
St Dev = 10.37 St Dev = 10.53
Median = 6 Median = 6
Range = 5 to 37 Range = 1 to 62
Mode = 6 Mode = 6
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1.9:1, which compares well with pooled data on JDM pa-
tients from diverse geographical areas especially, around
North America, showing a gender ratio of 1.5:1 to 2.3:1
[17-20]. In contrast, the female to male ratio in the United
Kingdom and Ireland has been reported as high as 5:1
[21]. In our study, the female to male ratio of patients with
onset ≤ 3 years was more skewed towards females (3.5:1)
as compared to the older onset group (1.4:1). The age-
dependent variation in the sex ratio has been widely
reported in published literature [6-8,17-21]. In our study
population the younger onset group had no seasonal clus-
tering of disease onset. Sixty percent of these patients had
fever preceding the onset of JDM. In contrast, the older
onset group of JDM patients in our study population did
have a seasonal clustering of the onset of disease during
the late winter and spring, and only 38.9% had preceding
fever. These findings may suggest the possibility of different
etiological agents or environmental factors playing a signifi-
cant role in disease pathogenesis in the two age groups,
perhaps agents and factors that have been discussed in
previous studies or ones not yet discovered [22-25].A significantly higher proportion of patients in the
younger onset group of children presented without typ-
ical JDM rash or nailfold capillary loop abnormalities
(Table 8). It is well known that onset of rash and
myositis can be discordant in JDM [26,27]. In patients
presenting without typical cutaneous manifestations of
JDM, muscle biopsy was performed in 6 patients to rule
out other muscle diseases and confirm a diagnosis of
JDM (Table 8 and Figure 2). Another difference was that
the younger onset group had less frequent muscle en-
zyme elevation at diagnosis. The diagnosis was not sig-
nificantly delayed in the younger onset group compared
to the older, though there was a trend for the younger
group to have a longer time period from onset of the
symptoms to diagnosis (5.7, 4.5 months).
Others have speculated that differences in disease trig-
ger or host responsiveness to a trigger, genetic influences,
or host maturity may affect disease course and outcome
in JDM [28,29]. The differences we found between the
younger and older onset groups may be reflective of such
factors, but further speculation based on our results
is not warranted.
Table 8 Histochemical findings of biopsy tissue of patients who did not have classic JDM rash (heliotrope, nail bed





















DM1 + + + + +




DM3 + + + + +
DM4 + + + + +
DM5 + + + + +
DM6 - + + + + Received two IV
pulse steroids
before biopsy
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younger onset group were admitted to the hospital and
given intravenous pulse steroids at diagnosis, suggesting
that younger patients may not have appeared to have
very severe disease at presentation. It could also be that
younger patients took a little more time to diagnose as
most were evaluated only on an outpatient basis and
over a longer time period.
In our study population, the initial dose of oral prednis-
one (mg/kg/day) and the proportion of patients treated
with methotrexate at diagnosis were the same in the
younger and older onset groups. This similarity may be a
reflection of the standard of practice in this rheumatology
division, or it may suggest a relative similarity in disease
severity at onset in these groups of patients, despite the
difference in hospitalization rate. The treatment was
uniform within our group as any pediatric rheumatology
center as a great majority of the patients were seen by two
pediatric rheumatologists working closely together.Figure 2 Histological features of muscle biopsy in JDM.We found that patients in the younger onset group were
more likely to have a monocyclic course and less likely to
have active disease at 5 and 10 years from diagnosis. In un-
published data from a recent study from UK, there was no
evidence that patients with younger age of onset had a worse
disease course and outcome [30]. Both the more recent UK
report and our findings contradict a previous report sug-
gesting that a younger age of onset in JDM is associated
with greater severity of disease and poorer outcome [31].
A significantly lower proportion of patients in the
younger onset group of children received hydroxychloro-
quine as compared to the older onset group of children.
This result again might be influenced by institution-based
practices, and/or by the fact that younger children have
difficulty taking a medication that is readily available only
in pill form. Another explanation could be reluctance to
prescribe hydroxychloroquine to younger patients due
to greater difficulty in identifying and monitoring retinal
toxicity.
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other immunosuppressive medications in general (IVIG,
TNF inhibitors, MMF, CSA, cyclophosphamide or
azathioprine) was the same in the two groups. Rituximab
was used in only two patients, and cyclophosphamide in
only one patient, all in the older onset group of children.
The reason for the use of these aggressive treatments in
only the older patients could have been more resistant
disease in this group, reluctance to use these medica-
tions in younger children, or skewing based on the pres-
ence of many fewer children in the younger group.
We looked at the means, medians, and longest dura-
tions of steroids and methotrexate courses in the two
groups. There was a significant difference in the length
of methotrexate and of steroid therapy between two
groups. Patients from the older onset group of children
received longer courses of both the drugs. This differ-
ence is consistent with the observation that the older
onset group had a more protracted disease course.
There were trends towards an increased incidence of
several complications in the younger onset group, and to-
wards more calcinosis in the older onset group. The only
difference in complication rate that reached statistical sig-
nificance was osteonecrosis, which was higher in older
onset patients. These patients received a higher average
cumulative steroid dose, possibly increasing their risk for
osteonecrosis. Their more protracted courses with more
remissions and relapses, and presumably longer duration
of active inflammation, also may have increased their risk
for calcinosis. The younger group had a higher rate of
mortality perhaps due to their higher vulnerability or
higher number of ulcerative JDM in the younger age
group (two in the younger and one in the older age group)
but the numbers are too small to draw any conclusions.
The survival analysis was performed to reduce the like-
lihood of bias that subjects have been censored (some
of the subjects had not experienced the outcome of
interest by the end of the followup period of ten years
because they had dropped out, i.e. discharged, lost to
followup, or died before reaching the outcome of inter-
est). The younger group had less chance of this bias and
had better followup.
The JDM disease with onset at three years or below was
different than that of older children at our center. These
may be ethnic factors or other epidemiological influences
that may be unique to our area. In spite of two deaths, it
would appear that the younger onset group did better
overall in multiple parameters. The outcome was different
for patients with ulcerative disease in the two groups in
our study. The incidence of ulcerative disease was higher
in younger onset population, as was the mortality in the
patients with ulcerative disease compared to older onset
JDM patients. Previously, different from our results, re-
searchers have reported conflicting results. There has beenno difference or worse disease in the younger group when
the age of onset cutoff of 5 years was used between the
two groups for comparison [23,24]. They also reported
more use of cyclophosphamide and anti TNF-α in the
younger onset JDM patients compared to older onset
group of patients, which may suggest higher incidence of
aggressive disease. They did not report explicitly on the
ulcerative disease or mortality in their population.
A limitation of our study is that it is a retrospective
study with variability in the clinical practice of the
rheumatologists. Diagnostic approaches and treatment
programs varied and may have had effects on disease re-
sponse and course. Rheumatologists in the group all
evaluated each patient by history, physical exam, and
muscle enzymes but varied in the evaluation of the JDM
patients by EMG, muscle biopsy, and MRI. Another
limitation was that this is a single center report with 19
JDM patients in the 3 years or younger onset group.
False positives are possible in a small research popula-
tion. This is a statistical drawback but in the rare disease
such as JDM, 19 patients with a disease onset at 3 years
or below is unusual and worth studying.
Conclusions
There were significant differences between JDM patients
at our center with disease onset at or below age three
years compared to their older counterparts. Younger
patients in our cohort had fewer typical findings at diag-
nosis. They were more likely to experience a monocyclic
course, a shorter and milder total disease course, and a
shorter maximum duration of oral steroid and metho-
trexate therapy. Younger patients had predominantly
monocyclic disease, and a lower proportion had active
disease at 5 and 10 years. In spite of having a milder dis-
ease course overall, patients with younger onset had a
higher mortality rate and a similar complication rate
compared to the older onset patients, except for a sig-
nificantly higher frequency of osteonecrosis in the older
onset group. These differences in the mortality rate de-
serve further study with a larger sample size. We should
continue to follow these younger children carefully and
watch for ulcerative disease from the time of their diag-
nosis. Despite this mortality concern, our overall find-
ings do differ from the previous report that a younger
age of onset in JDM is usually associated with a more se-
vere disease. These younger age children are atypical at
our center, but do better than their older counterparts.
Appendix A
First fatal case of JDM
She was a 3-year-old African American female who pre-
sented with arthritis and moderate muscle weakness. The
significant positives and negatives in her physical examin-
ation and investigations were: positive nail bed capillary
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http://www.ped-rheum.com/content/10/1/34changes but no gottron or heliotrope, and a history of pre-
ceding fever. Her aldolase and creatine kinase (CK) was
moderately elevated but AST and LDH were normal. Her
ESR was 43, CBC was normal except mild normocytic nor-
mochromic anemia, her ENA’s were negative, and the anti-
PSM/SLE test was indeterminate. Her myositis specific
antibody panel was negative; an ANA titer was 1:1280
(speckled). A blind quadriceps biopsy showed patchy chro-
nic inflammatory infiltrates and necrosis in perivascular
perifascicular- perimysium regions with myofibril regenera-
tion at various stages. There was reduced number of small
vessels/capillaries with vasculopathic changes. She had
histology-proven lipodystrophy at both prepatellar areas in
the lower limbs. The fiber type and proportion was
normal. There were no MAC-positive endomysial capil-
laries seen by immunoflourescence. There was minimal
perimysial fibrosis and muscle atrophy also seen. There
was no accumulation of glycogen, no abnormal inclu-
sions, no vacuoles, and no access lipid content found in
the myofibrils. The muscle biopsy was reported as
consistent with JDM.
During her 2.9 year-long disease course, she was treated
with pulse steroids, oral steroids, methotrexate, azathiopr-
ine and IVIG. Compliance was always an issue with her.
She did not show any clinical evidence of internal organ
involvement. She had a difficult and resistant to treatment
disease course. In her last few months she missed several
appointments.
One morning she was brought dead in emergency
room (ER). The autopsy findings confirmed severe skel-
etal muscle inflammation with typical JDM histopath-
ology. She also had chronic inflammatory changes in
proximal skeletal muscle part of esophagus and acute-
on-chronic gastritis (H. Pylori negative) with lymphoid
hyperplasia of the terminal ilium. Histopathologically,
her CNS was normal, but her heart was enlarged and
had a patchy mixed inflammatory infiltrate in the myo-
cardium with patchy myocardial necrosis. The infiltrate
consisted of lymphocytes, histiocytes, and neutrophils.
The areas of inflammation also showed contraction band
necrosis. There was myocyte injury and necrosis sur-
rounded by inflammatory cells in the myocardium. The
pericardium was thickened and showed chronic inflam-
mation and a moderate amount of pericardial effu-
sion. The lungs showed chronic inflammatory infiltrates
(mainly lymphocytes), mostly in the bronchi, bronchioles
and interstitial tissue. A patch of consolidation is seen in
right upper lobe. Her cause of death was ascertained as
fulminating JDM disease activity and inflammation.
Appendix B
Second fatal case of JDM
She was a caucasian female with an age of onset of JDM
of 18 months. She started with an unusual presentation ofhaving recurrent ulcerated lessons on the skin and tongue.
She lost a part of the tip of the tongue in the process
of healing. The histology of the skin ulcers showed
no lupus band but a lymphocytic infiltrate and classic
vasculopathic changes in the microvasculature. There was
prominent angiocentric infiltrate composed of activated-
appearing lymphocytes and histiocytes associated with en-
dothelial swelling.
She had no muscle weakness at the time. Her skin fin-
dings included a heliotrope rash which was photosen-
sitive in nature. She did not have a Gottron’s rash or
remarkable nail bed capillary changes. After extensive
negative investigations for infections, her PCP imperi-
ally treated her with repeated courses of oral steroids.
She relapsed when steroids were discontinued. After
6 months of initial symptoms, she sub-acutely developed
moderate muscle weakness, difficulty in speaking and
swallowing, and some loss of balance. She was referred
to rheumatology.
At that time the significant positives and negatives
from her physical examination and investigations were:
negative ANA, normal ESR, normal CK & aldolase, nor-
mal Von Willibrand antigen, normal GGT and ALT but
moderately elevated AST and LDH. A Factor VIII anti-
gen and von Willibrand antigen were elevated suppor-
ting JDM. Myositis-specific antibodies were negative. An
MRI of the pelvic girdle on the JDM protocol showed
substantial calcification in the muscles along with in-
creased T2 signal in quadratus labiorum, erector spinae,
iliopsoas, iliacus and inferior psoas suggesting ongoing,
uncontrolled muscle inflammation. Extensive calcification
was also found in costovertebral junctions, paraspinal
muscles and anterior longitudinal ligaments. The biopsy
of the paraspinal muscles was non-contributory as it was
reported as extensive muscle degeneration and atrophy in-
volving the majority of the histology section with a mi-
nimal perivascular inflammatory infiltrate.
She was treated with pulse steroids, oral steroids,
IVIG, and methotrexate for her illness. She had a diffi-
cult disease course, which only lasted for seven months.
A bowel perforation due to vasculopathy and ischemic
necrosis of her small intestine occurred and she devel-
oped a subdiaphragmatic abscess. She was hospitalized
and recovered from this episode of illness and was
discharged home. A few weeks later she was found dead
in the bed. The autopsy report included: Her diaphragm
showed chronic inflammation and was adherent to un-
derlying liver. Several intra-abdominal adhesions bet-
ween bowel loops and bowel wall were present. A
healing subdiaphragmatic abscess, evidence of previous
bowel resection, sub-capsular renal acute inflammatory
process and significant cardiomegaly was also noted. The
cause of death reported was also acute fulminating JDM
disease and inflammation.
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